BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer’s disease.
The company is collaborating with local companies and healthcare providers to distribute the ulcer test.
A Medical University of South Carolina team reports in Frontiers in Immunology that it has engineered a new type of genetically modified immune cell that can precisely target and neutralize antibody-producing cells complicit in organ rejection.
Swansea University has helped uncover a surprising new role for platelets—one that could significantly advance early cancer detection.
Researchers at Columbia Engineering have built a cancer therapy that makes bacteria and viruses work as a team. In a study published in Nature Biomedical Engineering, the Synthetic Biological Systems Lab shows how their system hides a virus inside a tumor-seeking bacterium, smuggles it past the immune system, and unleashes it inside cancerous tumors.
A new study, led by researchers at Children’s Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that are missing in pediatric high-grade glioma tumors but not in normal brain tissues.
Researchers have discovered eight new genes associated with schizophrenia, in the largest exome-sequencing study of the disorder ever conducted. The breakthrough, made by scientists at the Centre for Neuropsychiatric Genetics and Genomics (CNGG) at Cardiff University, provides new information and improves the understanding and future treatment development for schizophrenia.
The FDA has granted breakthrough device designation to SpinaFX Medical’s Triojection system, a minimally invasive treatment for contained lumbar disc herniations.
MicroPort NeuroScientific has launched its Numen coil embolization system in Egypt through a partnership with PentaMed.
The brain imaging study found that changes in brain dopamine are linked to symptoms of psychosis, no matter whether a person has been diagnosed with schizophrenia, bipolar disorder, or major depression.